Your session is about to expire
← Back to Search
Exparel for Non-Small Cell Lung Cancer (BEMP Trial)
Phase 3
Waitlist Available
Led By Traves Crabtree, MD
Research Sponsored by Southern Illinois University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adult at least 18 years of age
Subject needs elective lobectomy for non small cell lung cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 hours post surgery
Awards & highlights
BEMP Trial Summary
This study is evaluating whether two different types of local anesthetics may help reduce pain and the need for opioid medications after surgery.
Eligible Conditions
- Non-Small Cell Lung Cancer
- Lung Cancer
BEMP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBEMP Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 72 hours post surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours post surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Total Morphine Equivalents Consumed
Secondary outcome measures
Mortality
Pharmacy Cost
Treatment Cost
+1 moreOther outcome measures
Atrial Fibrillation/Other Arrhythmia
Hospital Stay
Pneumothorax
+1 moreBEMP Trial Design
2Treatment groups
Active Control
Group I: ExparelActive Control1 Intervention
Group II: MarcaineActive Control1 Intervention
Find a Location
Who is running the clinical trial?
Southern Illinois UniversityLead Sponsor
36 Previous Clinical Trials
15,194 Total Patients Enrolled
Traves Crabtree, MDPrincipal InvestigatorProfessor of Surgery
Stephen Hazelrigg, MDStudy DirectorProfessor of Surgery
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger